Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.
Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.
Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.
The Zoetis Foundation announced its first round of 2023 grants totaling
Zoetis Inc. (NYSE: ZTS) is set to host a webcast and conference call on May 4, 2023, at 8:30 a.m. (ET) to discuss its first quarter 2023 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from financial analysts. Interested investors and the public can access the live webcast through the Zoetis website, and a replay will be available following the event. In 2022, Zoetis generated impressive revenue of $8.1 billion and continues to lead in animal health innovation across over 100 countries.
Zoetis (NYSE:ZTS) will participate in the TD Cowen Health Care Conference on March 6, 2023. Wetteny Joseph, Executive Vice President and CFO, is set to present at 11:10 a.m. ET and address questions from analysts. A live audio webcast will be available at investor.zoetis.com/events-presentations. Following the event, a replay will be accessible on the Zoetis website. As a leading animal health company, Zoetis focuses on enhancing animal care globally, with $8.1 billion in revenue in 2022 and around 13,800 employees.
Zoetis has secured a $15.3 million grant from the Bill & Melinda Gates Foundation to enhance veterinary care and livestock productivity in Sub-Saharan Africa. This funding will broaden the existing African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative to include aquaculture and expand into seven new countries, including Ethiopia, Nigeria, Tanzania, Uganda, and Kenya. Over five years, the program aims to train 100,000 stakeholders and improve access to veterinary products, especially for female farmers. This initiative is part of Zoetis' commitment to support sustainable agricultural practices in rapidly developing regions.
Zoetis (NYSE: ZTS) will participate in the Bank of America Securities 2023 Animal Health Summit on March 2, 2023, at 12:30 p.m. ET. The company will be represented by Wetteny Joseph, Executive VP and CFO, who will answer questions from analysts. A live audio webcast will be available for interested parties at investor.zoetis.com/events-presentations. A replay will also be accessible after the event. Zoetis, a leading global animal health company, focuses on advancing animal care and reported revenues of $8.1 billion in 2022.
Zoetis reported its financial results for Q4 and the full year of 2022, achieving a revenue of $2.0 billion for Q4, up 4% year-over-year. The company’s net income for Q4 was $461 million, equating to $0.99 per diluted share. For the full year, Zoetis posted revenues of $8.1 billion, also reflecting a 4% increase, with net income reaching $2.1 billion or $4.49 per diluted share. Looking ahead, Zoetis expects 2023 revenue between $8.575 billion and $8.725 billion, with an operational growth forecast of 6% to 8%. Key growth drivers included companion animal products, although livestock product sales faced challenges from competition and supply issues.